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site-on the vesicular monoamine transporter (VMAT 2) binds 
to vesicle membranes from rat striatum. Lobeline inhibits 
[3H]DTBZ binding With an IC5O of 0.90 nM, consistent With 
its IC5O of 0.88 nM for inhibition of [3H]DA uptake into 
vesicles. These results suggest that the action of lobeline is 
similar to that of amphetamine and that it speci?cally 
interacts With DTBZ sites on VMAT2 to inhibit DA uptake 
into synaptic vesicles. d-amphetamine inhibits [3H]DTBZ 
binding to vesicle membranes With an IC5O of 39.4 nM, a 
concentration 20 times greater than reported for inhibition of 
VMAT2 function, suggesting that d-amphetamine interacts 
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monoamine uptake. These results suggest the use of lobeline 
and analogs thereof in treating individuals for diseases and 
pathologies of the central nervous system. 
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USE OF LOBELINE COMPOUNDS IN THE 
TREATMENT OF CENTRAL NERVOUS 
SYSTEM DISEASES AND PATHOLOGIES 
REFERENCE TO RELATED APPLICATION 
This application is a continuation-in-part of US. patent 
application Ser. No. 08/795,852, ?led Feb. 5, 1997 US. Pat. 
No. 5,830,904. 
FIELD OF THE INVENTION 
The present invention relates to the use of lobeline and 
analogs thereof in the treatment of diseases and pathologies 
of the central nervous system (CNS). The invention also 
relates to the treatment of drug abuse and WithdraWal 
therefrom, as Well as eating disorders, such as obesity. 
BACKGROUND OF THE INVENTION 
Lobeline (ot-lobeline) is a lipophilic, non-pyridino, alka 
loidal constituent of Indian tobacco (Lobelia in?ata). As 
shoWn by the folloWing formulas, no obvious structural 
resemblance to S(—)nicotine is apparent: 
Structure-function relationships betWeen nicotine and 
lobeline do not suggest a common pharmacophore (BarloW 
and Johnson, 1989). Nonetheless, lobeline has been reported 
to have many nicotine-like effects including tachycardia and 
hypertension (Olin et al., 1995), bradycardia and hypoten 
sion in urethane and pentobarbital anesthetiZed rats (Sloan et 
al., 1988), hyperalgesia (Hamann and Martin, 1994), mid 
olytic activity (Brioni et al., 1993), and improvement of 
learning and memory (Decker et al., 1993). Moreover, 
lobeline has been used as a substitution therapy for tobacco 
smoking cessation (Nunn-Thompson and Simon, 1989; 
Prignot, 1989; Olin et al., 1995); hoWever, its effectiveness 
is controversial as re?ected by both positive (Dorsey, 1936; 
KalyuZhnyy, 1968) and negative reports (Wright and 
Littauer, 1937; Nunn-Thompson and Simon, 1989). 
Furthermore, only short-term usage of lobeline as a smoking 
deterrent has been recommended due to its acute toxicity 
(nausea, severe heartburn and diZZiness) and the lack of 
information concerning its long-term usage (Wright and 
Littauer, 1937; Olin et al., 1995). 
In behavioral studies, nicotine has been shoWn to increase 
locomotor activity (Clarke and Kumar, 1983a, 1983b; 
Clarke, 1990; Fung and Lau, 1988), and to produce condi 
tioned place preference (Shoaib et al., 1984); Fudala et al., 
1985) in rats. HoWever, the results of the latter studies are 
controversial (Clarke and Fibiger, 1987). In contrast, 
lobeline does not increase locomotor activity (Stolerman et 
al., 1995) or produce conditioned place preference (Fudala 
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and IWamoto, 1986). Although initially lobeline Was shoWn 
to generaliZe to nicotine in discrimination studies (Geller et 
al., 1971), most subsequent studies have failed to reproduce 
this original ?nding (Schechter and Rosecrans, 1972; 
Reavill et al., 1990; Romano and Goldstein, 1980). 
Nicotine has been reported to be avidly self-administered 
by rats (Corrigal et al. 1992, 1994; Donny et al., 1996); 
hoWever, the ability of lobeline to support self 
administration has not been investigated. Based on the 
differential effects of lobeline and nicotine in behavioral 
studies, it appears that these drugs may not be acting via a 
common CNS mechanism, even though lobeline is often 
considered to be a nicotinic agonist (Decker et al., 1995). 
The positive reinforcing effect of nicotine is believed to be 
due to the activation of central dopaminergic systems 
(BoWell and Balfour, 1992; Corrigal et al., 1992, 1994). 
Presynaptic nicotinic receptors have been found on dopam 
ine (DA)-containing nerve terminals (Giorguieff-Chesselet 
et al., 1979; Clarke and Pert, 1985). Nicotine binds to 
nicotinic receptors With high affinity (Kd=1—7 nM) 
(Lippiello and Fernandes, 1986; Reavill et al., 1988; Romm 
et al., 1990; Bhat et al., 1991; Loiacono et al., 1993; 
Anderson and Arneric, 1994). Also, lobeline has been 
reported to displace [3H]nicotine binding from central nico 
tinic receptors With high affinity (Ki=5—30 nM) (Yamada et 
al., 1985; Lippiello and Fernades, 1986; Banerjee and 
Abood, 1989; Broussolle et al., 1989). 
Chronic treatment With nicotine results in an increase in 
the number of nicotinic receptors in many regions of rat and 
mouse brain (Collins et al., 1990; Bhat et al., 1991, 1994; 
Marks et al., 1992; Sanderson et al., 1993). An increase in 
the number of nicotinic receptors in postmortem human 
brain tissue obtained from smokers also has been reported 
(BenWell et al., 1988). In contrast, chronic lobeline admin 
istration did not increase the number of nicotinic receptors 
in mouse brain regions in Which increases Were observed 
folloWing chronic nicotine administration (Bhat et al., 
1991). 
Nicotine evokes DA release in in vitro superfusion studies 
using striatal slices (Westfall, 1974; Giorguieff-Chesselet et 
al., 1979; Westfall et al., 1987; Harsing et al., 1992) and 
striatal synaptosomes (Chesselet, 1984; RoWell et al., 1987; 
Rapier et al., 1988, 1990; Grady et al., 1992, 1994; RoWell 
and Hillebrand, 1992, 1994; RoWell, 1995), and in in vivo 
studies using microdialysis in striatum (Imperato et al., 
1986; Damsma et al., 1989; BraZell et al., 1990; Toth et al, 
1992). Nicotine-evoked DA release is calcium-dependent, 
mecamylamine-sensitive and mediated by nicotinic recep 
tors (Giorguieff-Chesselet et al., 1979; Westfall et al, 1987; 
Rapier et al., 1988; Grady et al., 1992). Mecamylamine is a 
noncompetitive nicotinic receptor antagonist, Which more 
effectively blocks the ion channel of the receptor (Varanda 
et al., 1985; Loiacono et al., 1993; Peng et al., 1994). Similar 
to nicotine, lobeline has been reported to increase DA 
release from superfused rat and mouse striatal synaptosomes 
(Sakurai et al., 1982; Takano et al, 1983; Grady et al., 1992). 
Based on these neurochemical studies, lobeline Was sug 
gested to be an agonist at nicotinic receptors (Decker et al., 
1995). It is difficult to reconcile that nicotine and lobeline 
similarly release DA and displace [3H]nicotine binding; 
hoWever, the observed upregulation of nicotinic receptors 
folloWing chronic nicotine administration is not observed 
folloWing chronic lobeline administration. 
Earlier studies of the pharmacokinetic properties of 
lobeline have centered on its proposed use in the treatment 
of nicotinism. For example, US. Pat. Nos. 5,536,503; 5,486, 
6,087,376 
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362; 5,403,595; and PCT Publication WO 92/19241 are all 
related to a drug delivery system and method for treating 
nicotine dependence. US. Pat. Nos. 5,414,005; 4,971,079; 
and 3,901,248 also discuss the use of lobeline in the context 
of treating nicotine abuse and/or addiction. A scienti?c 
article has studied the actions of morphine, lobeline, and 
other drugs in inducing “analgesia” in rats (S. Hamann et al. 
1994). HoWever, these Workers did not equate their ?nding 
of an “analgesic” response for lobeline to a reduction of the 
pain response in man, nor did they propose the use of 
lobeline in treating drug abuse, WithdraWal from addiction, 
and the like. 
Similarly, to the present inventors’ knowledge, the use of 
lobeline in the treatment of eating disorders has not been 
proposed. This is in spite of the Widely accepted ability of 
nicotine to suppress appetite (see, e.g., Remington’s Pharm. 
Sci., 18th ed., p.891) and the previously proposed associa 
tion of obesity With reduced bioavailability of dopamine 
(US. Pat. Nos. 5,552,429; 5,576,321; 5,272,144; and 5,468, 
755). 
The present study further elucidates the mechanism of 
action of lobeline using [3H]dihydrotetrabenaZine DTBZ), a structural analog of tetrabenaZine (TBZ), Which 
binds to a single class of high-af?nity sites on the vesicular 
monoamine transporter-2 protein (VMAT2) to inhibit 
vesicular DA uptake (Pletscher et al., 1962; Scherman et al., 
1986; Kilbourn et al., 1995; Liu et al., 1996). Of note, TBZ 
does not alter spontaneous efflux of [3H]DA from rat brain 
vesicles (Floor et al., 1995). Taken together, TBZ appears to 
block [3H]DA uptake into vesicles but does not promote 
[3H]DA release from vesicles. 
In the present study, the effect of lobeline is compared 
With that of d-amphetamine, a psychostimulant and lipo 
philic Weak base reported to inhibit DA uptake into striatal 
synaptic vesicles (Philippu and Beyer, 1973; Ary and 
Komiskey, 1980) and to inhibit monoamine uptake into 
human VMAT2 expressed in CV-1 cells (Erickson et al., 
1996). d-Amphetamine has also been reported to release DA 
from synaptic vesicles of the Planorbis corneas giant DA 
cell, increasing DA concentrations in the cytosol and pro 
moting reverse transport of DA via DAT (SulZer and 
Rayport, 1990; SulZer et al., 1995). Furthermore, 
d-amphetamine has been reported to inhibit [3H]DTBZ 
binding to rat striatal homogenates (Rostene et al., 1992) and 
human VMAT2 expresed in COS cells (GonZaleZ et al., 
1994), but With loW potency. The ability of lobeline to evoke 
[3H]DA release from rat striatal synaptic vesicles preloaded 
With [3H]DA is also assessed in the present study. 
SUMMARY OF THE INVENTION 
The present invention is for a method of treating an 
individual Who suffers from a disease or pathology of the 
central nervous system (CNS). The method comprises 
administering to the individual an amount of a lobeline 
compound, i.e., lobeline, analogs, and derivatives thereof, 
including pharmaceutically acceptable salts. The amount of 
lobeline compound administered is effective to alleviate at 
least one of the symptoms of the individual’s condition. 
The lobeline compound can be administered alone, com 
bined With an excipient, or coadministered With a second 
drug having a similar or synergistic effect. The compound or 
composition is preferably administered subcutaneously, 
intramuscularly, intravenously, transdermally, orally, 
intranasally, or rectally. 
The utility of lobeline, analogs, and derivatives thereof, 
e.g., those that form lobeline upon metabolism by the body, 
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in treating dependencies on drugs of abuse is implicated by 
the present studies. In particular, the treatment of dependen 
cies on such drugs as cocaine, amphetamines, caffeine, 
phencyclidine, opiates, barbiturates, benZodiaZepines, 
cannabinoids, hallucinogens, and alcohol is implicated. 
Also, the treatment of eating disorders, such as obesity, is 
implicated. In a preferred aspect of the invention, the 
method of treatment reduces an individual’s desire for the 
drug of abuse or for food by at least one day. 
A lobeline compound of the present invention is contem 
plated primarily for use in the treatment of diseases and 
pathologies associated With the CNS. Thus, cognitive 
disorders, head or brain trauma, memory loss, psychosis, 
sleep disorders, obsessive-compulsive disorders, panic 
disorders, myasthenia gravis, Parkinson’s disease, AlZhe 
imer’s disease, schiZophrenia, Tourette’s syndrome, Hun 
tington’s disease, and attention de?cit disorder, and related 
conditions are considered to be susceptible to treatment With 
a lobeline compound of the present invention. 
As shoWn by the results of the studies described herein, 
and contrary to conventional belief, lobeline is found to act 
at higher concentrations primarily not as a nicotinic agonist, 
but by a different mechanism than is observed for nicotine. 
The present studies also suggest that lobeline may be 
effective in inhibiting uptake of extracellular dopamine by 
cells of the CNS, perhaps by blocking dopamine receptors 
on the cells. Either or both mechanisms can thereby Work to 
increase the extracellular concentration of dopamine. Many 
respects in Which the actions of lobeline are similar to those 
of amphetamine have been identi?ed. 
BRIEF DESCRIPTION OF THE FIGURES 
FIGS. 1A and 1B depict the time course of nicotine 
evoked fractional release (A) and concentration-dependence 
of nicotine-evoked total [3H]over?oW (B) from rat striatal 
slices preloaded With [3H]DA (3,4-dihydroxyphenylethyl-2 
[N-3H]-amine). Nicotine Was added to the superfusion 
buffer after the second sample (as indicated by the arroW) 
and remained in the buffer until the end of the experiment. 
The data in FIG. 1A are presented as means:S.E. fractional 
release, Which represents the tritium in the sample as a 
percentage of the total tritium in the slice at the time of 
sample collection. The data in FIG. 1B are presented as 
mean:S.E. total [3H]over?oW, Which represents the area 
under the curve of the corresponding nicotine concentration 
response as a function of time. §P<0.05, different from basal 
(5—10 min), When fractional release Was collapsed across 
nicotine concentration; *P<0.05, signi?cantly different from 
0—0.01 pM and 1—100 pM; **P<0.05, different from 0—0.1 
pM and 100 pM; ***P<0.05, different from 0—10 pM; 
Duncan’s NeW Multiple Range Test. n=4—9 rats. 
FIGS. 2A and 2B depict the time course of lobeline 
evoked fractional release from rat striatal slices preloaded 
With [3H]DA. Lobeline Was added to the superfusion buffer 
after the collection of the second sample (as indicated by the 
arroW) and remained in the buffer until the end of the 
experiment. Data are presented as mean:S.E. fractional 
release, Which represents the tritium in the superfusate 
sample as a percentage of the total tritium in the slice at the 
time of sample collection. FIG. 2A illustrates the time course 
of the fractional release evoked by loW concentrations 
(0.01—3 pM) of lobeline, and FIG. 2B illustrates that evoked 
by high concentrations (3—100 pM). *P<0.05, different from 
basal out?oW; +P<0.05, different from the peak responses at 
25 min for 0.01—3 pM and 30—300 pM; §P<0.05, different 
from the peak responses of 0.01—10 pM and 100 pM; 
6,087,376 
5 
#P<0.05, different from the peak responses of 0.01—30 pM; 
Fisher’s LSD post hoc test. n=6 rats. 
FIG. 3 depicts the concentration-dependence of lobeline 
evoked total [3H]over?oW from rat striatal slices preloaded 
With [3H]DA. Data are presented as rnean:S.E. total [3H] 
over?ow, Which represents the area under the curve of the 
corresponding lobeline concentration-response as a function 
of time. The inset illustrates the total [3H]over?oW evoked 
by the loWer concentrations (0.01—1 nM) of lobeline. Con 
trol slices Which Were superfused With buffer in the absence 
of lobeline did not evoke [3H]over?oW (i.e. fractional 
release Was not different from basal during the course of 
superfusion). *P<0.05, different from control and each of the 
other lobeline concentrations; Duncan’s NeW Multiple 
Range Test. n=6 rats. 
FIG. 4 depicts the time course of the effect of rnecarny 
larnine to inhibit nicotine(10 nM)-evoked fractional release 
of [3H]DA frorn preloaded rat stratal slices. For clarity of 
graphical presentation, only signi?cant effects of the loWest 
and highest concentration, 0.01 and 100 pM, respectively, of 
rnecarnylarnine are illustrated. Data are presented as 
rnean:S.E. fractional release as percentage of basal out?oW. 
Experiments were performed as described in Table 2 here 
inbeloW. The time course begins at the time of nicotine (10 
pM) addition to the superfusion buffer containing rnecarny 
larnine. The control represents fractional release in the 
absence of either rnecarnylarnine or nicotine in the super 
fusion buffer. Duncan’s NeW Multiple Range Test revealed 
a signi?cant inhibitory effect of 0.01 pM rnecarnylarnine, 
When the data Were collapsed across time of superfusion. 
n=8 rats. 
FIG. 5 depicts the effects of nicotine (0.01—1000 pM) and 
lobeline (0.01—1000 pM) on rat striatal synaptosornal and 
synaptic vesicular [3H]DA uptake. III nicotine, synaptoso 
rnal [3H]DA uptake; I nicotine, vesicular [3H]DA uptake; O 
lobeline, synaptosornal [3H]DA uptake; O lobeline, vesicu 
lar [3H]DA uptake. Data are presented as rnean:S.E. per 
centage of total [3H]DA uptake. Total [3H]DA uptake for 
synaptosornes and vesicles Was 10919.80 prnol/rnin/rng and 
13401717 prnol/rnin/rng, respectively. Non-speci?c [3H] 
DA uptake in synaptosornal and vesicular experiments was 
2% and 20%, respectively, of total [3H]DA uptake as deter 
mined by incubation With 10 pM GBR and incubation at 0° 
C., respectively. Experirnents examining the effect of nico 
tine on synaptosornal uptake included a loW concentration 
range (0.001—1 nM), hoWever, no effect Was observed and 
for clarity of graphical presentation these results are not 
illustrated. *P<0.05, different from total [3H]DA uptake; 
Dunnett’s post hoc test. n=3—6 rats. 
FIG. 6 depicts the endogenous DA and DOPAC 
(dihydroxyphenylacetic acid) content in rat striatal slices 
superfused With high concentrations (30—100 nM) of 
lobeline. Endogenous DA and DOPAC content Were deter 
mined after 60 rnin superfusion With various concentrations 
of lobeline. Data are presented as rnean:S.E. ng/rng protein. 
*P<0.05, different from control, P<0.05, **P<0.001, differ 
ent from control; Dunnett’s post hoc test. n=8 rats. 
FIG. 7 depicts equilibrium binding of [3H]DTBZ to rat 
striatal vesicles. Striatal vesicles Were incubated for 10 min 
at 25° C. in the absence and presence of [3H]DTBZ (0.5—10 
nM) Nonspeci?c binding (0) was determined using 20 pM 
TBZ. Speci?c binding (O) Was de?ned as the difference 
betWeen total binding (not shoWn) and the nonspeci?c 
binding. Data are rneanzSEM prnol/rng protein. Inset: Scat 
chard transformation of the mean speci?c [3H]DTBZ bind 
ing data from the saturation analyses. n=4 experiments. 
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FIG. 8 depicts lobeline inhibition of [3H]DTBZ binding to 
rat striatal vesicles. Data represent the rneanzSEM prnol 
[3H]DTBZ bound/rng protein. Control represents the 
amount of [3H]DTBZ bound in the absence of lobeline. 
*p<0.05, signi?cantly different from control; Fisher least 
signi?cant difference post hoc test. n=5 experirnents. 
FIG. 9 shoWs that d-arnphetarnine inhibits [3H]DTBZ 
binding to rat striatal vesicles. Data represent the 
rneanzSEM prnol [3H]DTBZ bound/rng protein. Control 
represents the amount of [3H]DTBZ bound in the absence of 
d-arnphetarnine. *p<0.05, signi?cantly different from con 
trol; Fisher least signi?cant difference post hoc test. n=5 
experirnents. 
FIG. 10 shoWs the time course of spontaneous [3H]DA 
ef?ux frorn [3H]DA-preloaded striatal vesicles in the 
absence of drug. Data are expressed as rneanzSEM [3H]DA 
ef?ux as a percent of total [3H]DA content of the vesicles at 
time 0. n4 experirnents. 
FIG. 11 shoWs that d-arnphetarnine evokes [3H]DA 
release from synaptic vesicles preloaded With [3H]DA. 
d-Arnphetarnine-evoked vesicular [3H]DA release Was 
expressed as percent of control content. The total amount of 
[3H]DA present in control samples Was 4.37:1.06 prnol/rng 
protein. *p<0.05, signi?cantly different from control; Fisher 
least signi?cant difference post hoc test. n3 experirnents. 
FIG. 12 depicts lobeline inhibition of nicotine-evoked 
[3H]doparnine release from rat striatal slices. Striatal slices 
Were obtained from rat brain, preincubated With [3H] 
doparnine (0.1 nM) for 30 min and subsequently superfused 
With Kreb’s buffer for 60 rnin. FolloWing the initial period 
of superfusion, slices Were superfused With buffer contain 
ing various concentrations of lobeline for 30 min and 
subsequently various concentrations of nicotine Were 
included in the buffer. Superfusate samples were collected to 
determine the ability of lobeline to inhibit the nicotine 
induced response. 
FIG. 13 illustrates the current understanding of the pri 
rnary mechanism of the action of lobeline in the central 
nervous system. 
DETAILED DESCRIPTION OF THE 
INVENTION 
As used herein, the term “lobeline” refers to a compound 
having the general chemical formula 2-[G-([3 
hydroxyphenethyl)-1-rnethyl-2-piperidyl]-acetophenone. 
The term “lobeline” as used herein refers to the above 
compound in its free form, or as a salt thereof, Which has the 
physiological activity addressed. Inasmuch as a compound 
having this formula has three chiral centers, eight optical 
isomers of the compound can exist. HoWever, particular 
optical isorner(s) are not intended herein unless speci?cally 
mentioned. 
The term “lobeline analogs” and equivalents thereof, as 
used herein, refers to chemical derivatives of lobeline, such 
as those obtained by oxidation or reduction of lobeline, 
others obtained by esteri?cation of lobeline and its redox 
derivatives, as Well as various substitutions at the N-position 
of the piperidinyl group in the lobeline rnolecule. 
Preferred lobeline analogs, Which may act as prodrugs of 
lobeline itself When metabolized by the body, include those 
contemplated by formula (I) (Without regard to chirality): 
6,087,376 
(I) 
Where R1 and R2 each independently represents hydrogen, 
loWer alkyl, loWer alkenyl, loWer alkylcarbonyl, 
arylcarbonyl, e.g., phenylcarbonyl, aralkylcarbonyl, e.g., 
alkylphenylcarbonyl, loWer alkoxycarbonyl, loWer 
alkylaminocarbonyl, higher alkylcarbonyl, and poly 
(alkyleneoxide)carbonyl; R3 and R4 each independently 
represents hydrogen or combines With R1 and , 
respectively, to form a double bond; and X represents H or 
loWer alkyl. Whenever a carbonyl-containing substituent is 
provided as R1 or R2, it is understood that the carbonyl group 
is covalently bonded to the respective O atom appearing in 
formula Thus, in the instances Where the substituent is an 
alkoxycarbonyl or alkylaminocarbonyl, a carbonate or car 
bamate linkage is present in the molecule. 
Preferred substituents for R1 and R2 include methylcar 
bonyl (acetyl), phenylcarbonyl (benZoyl), natural fatty acid 
groups, e.g., palmitoyl, oleyl, linoleyl, stearyl, and lauryl, 
and polyethyleneglycol (PEG) covalently bonded to the 
molecule via a carbonate linkage. Long chain moieties such 
as a PEG group in a lobeline prodrug enhance transdermal 
delivery of the molecule, Which may be metaboliZed to 
lobeline and derivatives thereof. 
As used herein, the terms “loWer alkyl”, “loWer alkenyl”, 
“loWer alkoxy”, and the like, refer to normal, branched and 
cyclic hydrocarbyl groups containing 1 to 6 carbon atoms. 
The term “higher alkyl” includes alkyl groups containing 7 
to about 20 carbon atoms. The term “aryl” refers to a 
hydrocarbon group containing one or more aromatic rings, 
optionally substituted With one or more heteroatoms. The 
term “aralkyl” refers to an aryl group covalently bonded to 
a loWer alkyl group. 
It is, of course, contemplated that certain lobeline analogs 
having the above formula may be converted into a different 
molecule upon metabolism by the body. For example, When 
ever an acetyl group is present at R1 and/or R2 in the 
compound, the acetyl group may be removed by metabolic 
processes, e.g., such as occur in the gastrointestinal tract or 
the liver. The choice of substituents is subject to consider 
ations of toxicity, side effects, dosage, and the like. 
Particularly preferred lobeline analogs are those in Which 
(i) both R1 and R2 are H (i.e., a lobelanidine compound), (ii) 
either R1 or R2 is H and the other combines With R3 or R4 
to form a double bond (i.e., a lobeline compound), and (iii) 
both R1 and R2 combine With either R3 or R4 to form a 
double bond (i.e., a lobelanine compound). It is also pre 
ferred that X in the above formula represents a methyl 
group. Preferably, the chirality at the 2 and 6 positions of the 
piperidyl ring of the compounds is the same as in naturally 
occurring lobeline. 
Lobeline, as Well as analogs thereof, can be administered 
in its free base form or as a soluble salt. Whenever it is 
desired to employ a salt of lobeline or analog, it is preferred 
that a soluble salt be employed. Some preferred salts include 
the hydrochloride, hydrobromide, nitrate, sulfate, tartrate, 
fumarate, citrate, maleate, ascorbate, lactate, aspartate, 
mesylate, benZene sulfonate, propionate and succinate salts. 
Also, other anionic moieties such as fatty acid salts can be 
used, e.g., palmitate salt. 
As used herein, an “effective amount”, and similar usages, 
refers to an amount of a drug effective to reduce an indi 
vidual’s desire for a drug of abuse, or for food. 
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Apharmaceutical composition containing a lobeline com 
pound of the invention is also contemplated, Which may 
include a conventional additive such as a stabiliZer, buffer, 
salt, preservative, ?ller, ?avor enhancer, and the like, as 
knoWn to those skilled in the art. Representative buffers 
include phosphates, carbonates, citrates, and the like. Exem 
plary preservatives include EDTA, EGTA, BHA, BHT, and 
the like. 
A composition of the invention may be administered by 
inhalation, i.e., intranasally as an aerosol or nasal formula 
tion; topically, i.e., in the form of an ointment, cream or 
lotion; orally, i.e., in solid or liquid form (tablet, gelcap, time 
release capsule, poWder, solution, or suspension in aqueous 
or non-aqueous liquid); intravenously as an infusion or 
injection, i.e., as a solution, suspension, or emulsion in a 
pharmaceutically acceptable carrier; transdermally, e.g., via 
a transdermal patch; rectally, as a suppository, and the like. 
Generally, it is expected that a pharmacologically effec 
tive dose of a present compound Will require its adminis 
tration in an amount less than 1x10‘3 mg/kg of body Weight 
per day. The amount to be administered depends to some 
extent on the lipophilicity of the speci?c compound selected, 
since it is expected that this property of the compound Will 
cause it to partition into fatty deposits of the subject. The 
precise amount to be administered can be determined by the 
skilled practitioner in vieW of desired dosages, side effects, 
the medical history of the patient, and the like. It is antici 
pated that the compound Will be administered in an amount 
ranging from about 1x10“5 to about 1x10“3 mg/kg/day. 
The present study Was performed to determine the 
involvement of nicotinic receptors in lobeline-evoked [3H] 
over?oW from rat striatal slices preloaded With [3H]DA. The 
calcium-dependency of the effect of lobeline and the ability 
of mecamylamine to inhibit the lobeline response Were 
determined. To assess the contribution of potential effects on 
DA uptake, the effect of nicotine and lobeline to inhibit 
[3H]DA uptake into striatal synaptosomes and synaptic 
vesicle preparations Was also determined. Based on the 
present results of the in vitro superfusion studies, striatal 
dopamine (DA) and dihydroxy phenylacetic acid (DOPAC) 
content Were also determined after lobeline superfusion in 
vitro, and after lobeline administration in vivo. 
Effect of Nicotine on Superfused Rat Striatal Slices Pre 
loaded With [3H]DA. 
In a concentration-dependent manner, nicotine evoked an 
increase in the fractional release of tritium over the time 
course of the superfusion experiment (FIG. 1A). Repeated 
measures, tWo-Way AN OVA (analysis of variants) revealed 
a signi?cant main effect of nicotine concentration (F(8>429)= 
29.45, P<0.0001) and a signi?cant main effect of time 
(F10)429)=9.76, P<0.0001), but the concentration><time inter 
action Was not signi?cant (F(8O)42O)=1.22, P>0.05). Frac 
tional release peaked Within 10—15 min after the addition of 
nicotine to the superfusion buffer. From 10—25 min after the 
addition of nicotine, fractional release Was signi?cantly 
increased above basal out?oW, When the data Were collapsed 
across nicotine concentration. At peak fractional release, the 
highest concentration of nicotine examined increased frac 
tional release 2-fold above basal. Furthermore, When the 
data Were collapsed across nicotine concentration, fractional 
release, from 30—45 min after nicotine addition, Was not 
signi?cantly different from basal, despite the presence of 
nicotine in the superfusion buffer throughout the superfusion 
period. 
Presentation of the results as nicotine-evoked total [3H] 
over?oW accentuates the concentration-dependent nature of 
the response to nicotine (FIG. 1B). Repeated-measures, 
one-Way ANOVA revealed a signi?cant nicotine 
concentration effect (F(8)39)=25.77, P<0.0001). The loWest 
nicotine concentration Which evoked a signi?cant increase 
in [3H]over?oW Was 0.05 pM. A plateau in the 
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concentration-response curve was not apparent over the 
concentration range examined. Higher concentrations of 
nicotine were not examined because of the extensive work 
of Westfall and collaborators (Westfall, 1974; Westfall et al., 
1987) indicating that nicotine concentrations higher than100 
pM act to release DA from superfused rat striatal slices by 
a mechanism which is not calcium-dependent nor nicotinic 
receptor mediated. 
Effect of Lobeline on Superfused Rat Striatal Slices Pre 
loaded with [3H]DA. 
Lobeline evoked a marked concentration-dependent 
increase in fractional release of tritium over the time course 
of the superfusion experiment (FIG. 2). Repeated-measures, 
two-way AN OVA revealed a signi?cant main effect of 
lobeline concentration (F7)363=1057.13, P<0.0001), a sig 
ni?cant main effect of time (F1O)363)=132.24, P<0.0001) and 
a signi?cant concentration><time interaction (FOO)36 = 
44.85, P<0.0001). Low concentrations (0.01—1 pM) of 
lobeline did not signi?cantly increase fractional release 
during the entire superfusion period. Lobeline (3 pM) 
evoked a signi?cant increase in fractional release 15 and 20 
min after its addiction to the buffer. Subsequently, the 
fractional release returned towards basal, despite the con 
tinuous presence of lobeline in the buffer. Fractional release 
evoked by high concentrations (10—100 pM) of lobeline was 
signi?cantly increased 10 min after the addition of lobeline 
to the buffer and remained signi?cantly higher than basal 
until the end of the experiment. 
Of note is the magnitude of the response to lobeline in 
comparison to that observed after superfusion with nicotine. 
Peak fractional release after superfusion with 30 and 100 pM 
lobeline was approximately 15% and 30%, respectively, of 
the total tritium present in the striatal slice (FIG. 2B). 
Furthermore, over the remainder of the superfusion period, 
fractional release in superfusate samples continued to be 
10—20% of the total tritium in the slice. On the other hand, 
peak fractional release induced by the highest concentration 
(100 pM) of nicotine was only 2% of total tritium in the 
slice, and fractional release returned to basal during the 
course of the experiment (FIG. 1A). These results suggest 
the potential for depletion of DA storage pools following 
superfusion with lobeline at high concentrations. 
Expression of the results as total [3H]over?ow also 
revealed a concentration-dependent effect of lobeline and a 
marked increase in [3H]over?ow evoked by high concen 
trations of lobeline (FIG. 3). Repeated-measures, one-way 
AN OVA revealed a signi?cant lobeline concentration effect 
(F(6)35)=61.55, P<0.0001). The lowest concentration of 
lobeline to evoke a signi?cant increase in total [3H]over?ow 
was 1 pM. As the lobeline concentration was increased, a 
signi?cantly greater total [3H]over?ow was evoked. 
Furthermore, a plateau in the concentration-response curve 
was not apparent over the concentration range examined. 
Lobeline-induced [3H]over?ow: Lack of Calcium 
Dependency. 
Previous studies (Westfall, 1974; Westfall et al., 1987) 
reported that nicotine (<100 pM)-evoked [3H]over?ow from 
rat striatal slices preloaded with [3H]over?ow was calcium 
dependent. In order to determine if lobeline-induced [3H] 
over?ow was calcium-dependent, the effect of lobeline was 
determined in a calcium-free superfusion buffer containing 
0.5 mM EGTA (ethylene glycol-bis([3-aminoethyl ether)-N, 
N,N‘,N‘-tetraacetic acid (See Table 1). Two-way ANOVA 
revealed a signi?cant main effect of lobeline concentration 
(within-group factor, F(3>39)=473.08, P<0.001), however, the 
main effect of inclusion of calcium in the buffer was not 
signi?cant (between-groups factor, F(1>39)=0.13, P>0.05) 
and the interaction term also was not signi?cant (F(3)39)= 
1.64, P>0.05). Thus, the effect of lobeline on [3H]over?ow 
was not altered-following removal of calcium from the 
superfusion buffer. 
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TABLE 1 
Lobeline Evokes [3H] Over?ow from Rat Striatal Slices Preloaded 
with [3H] DA in a Calcium Independent Manner" 
Lobeline 
Concentration Control Buffer Calcium-Free Buffer 
0.1 0.6 r 0.4 0 z 0 
1 2.0 r 0.6 2.9 r 0.2 
10 31.9 r 2.2 45.0 r 4.2 
100 198.0 1 20 185.0 1 12.0 
*Concentration-response of lobeline was determined using either control 
Krebs’ buffer or calcium-free buffer with the addition of 0.5 mM EGTA. 
Data are presented as mean 1 SE. total [3H] over?ow, n = 6 rats/group. 
Nicotine-Evoked and Lobeline-Evoked [3H]Over?ow: 
Mecamylamine Antagonism. 
In a concentration-dependent manner, mecamylamine sig 
ni?cantly inhibited nicotine (10 pM)-evoked [3H]over?ow 
from rat striatal slices preloaded with [3H]DA (See Table 2). 
Repeated-measures, one-way AN OVA revealed a signi?cant 
mecamylamine concentration effect (F(5>38)=4.46, P<0.005). 
Concentrations of mecamylamine from 0.1—100 pM inhib 
ited (57%—5 91%) the effect of nicotine to evoke [3H] 
over?ow. 
The time course of the effect of mecamylamine illustrates 
the pattern and the extent of the inhibition of the nicotine 
evoked increase in fractional release (FIG. 4) Repeated 
measures, two-way AN OVA revealed a signi?cant main 
effect of mecamylamine concentration (F 6>599)=19.59, 
P<0.0001), a signi?cant main effect of time ( (11)599)=4.98, 
P<0.0001), but the concentration><time interaction was not 
signi?cant (F(66>599)=0.97, P>0.05). When the data were 
collapsed across time, the lowest concentration of mecamy 
lamine to produce a signi?cant inhibition of nicotine’s effect 
was 0.01 pM. The time course illustrates the small, but 
signi?cant, inhibition (36%) of nicotine’s effect produced by 
this low concentration of mecamylamine. Interestingly, the 
inhibitory effect of 0.01 pM mecamylamine was not detected 
when the results were expressed as total [3H]over?ow (See 
Table 2). The maximal inhibitory effect of the highest 
concentration (100 pM) of mecamylamine is also illustrated 
in FIG. 4 for comparison. 
TABLE 2 
Mecamylamine Inhibition of Nicotine(10 ,uM)-evoked [3H] Over?ow 
from Rat Striatal Slices Preloaded with [3H] DA" 
Mecamylamine Total [3H] Over?ow 
0 5.60 r 1.20 
0.01 3.57 r 1.52 
0.1 2.40 r 0.87" 
1 1.59 r 0.64** 
10 1.02 r 0.43** 
100 0.54 r 0.32** 
*Slices were superfused with buffer in the absence or presence of 
mecamylamine (0.01-100 ,uM)for 60 min, followed by 60 min superfusion 
with the addition of 10 ,uM of nicotine to the buffer containing the various 
concentrations of mecamylamine. Data are presented as mean : S.E. total 
[3H] over?ow. Total [3H] over?ow for slices superfused in the absence of 
any drug was 0.06 r 0.06. Slices superfused with nicotine (10 ,uM) in the 
absence of mecamylamine were considered control for statistical analysis. 
*P < 0.05, one-tailed, different from control; *"P < 0.05, two-tailed, differ 
ent from control; Dunnett’s post hoc test. n = 8 rats. 
The ability of mecamylamine (1—100 pM) to inhibit 
lobeline(0.1—100 pM)-evoked total [3H]over?ow is shown 
in Table 3. Concentrations of mecamylamine which signi? 
cantly inhibited nicotine-evoked [3H]over?ow were utiliZed 
in these experiments. The effect of lobeline (0.1—100 pM) in 
the absence of mecamylamine represented control. Two-way 
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AN OVA revealed a signi?cant main effect of lobeline con 
centration (within groups factor, F(4)56)=603.84, P<0.0001); 
however, both the main effect of mecamylamine concentra 
tion (between-groups factor, F(3)14)=2.79, P>0.05) and the 
lobeline><mecamylamine interaction were not signi?cant 
(F(12)56)=1.30, P>0.05). Thus, lobeline-evoked [3H]over?ow 
was not inhibited by mecamylamine. 
TABLE 3 
Lobeline-evoked [3H] Over?ow from Rat Striatal Slices Preloaded 
with [3H] DA is Not Inhibited bv Mecamvlamine" 
Meca 
myla 
mine Con 
centra- Lobeline Concentration (MM) 
tion (MM) 0.1 1 3 10 100 
0 0.6 r 0.4 2.0 r 0.6 10.3 r 0.8 31.9 r 2.2 185.0 1 12 
1 0.9 r 0.5 4.9 r 1.8 10.8 r 1.4 32.5 r 1.0 180.0 1 47.6 
10 0.8 r 0.3 2.4 r 0.5 8.2 r 1.5 41.0 r 6.2 179.5 1 12.2 
100 0.5 r 0.4 0.7 r 0.1 6.5 r 0.9 20.0 r 2.0 160.4 1 30.2 
*Slices were superfused with buffer in the absence or presence of 
mecamylamine (1-100 ,uM) for 60 min, followed by 60 min superfusion 
with the addition of lobeline (0.1-100 ,uM) to the buffer. Data are pre 
sented as mean : S.E. total [3H] over?ow. n = 4-6 rats. 
The Effect of Nicotine and Lobeline on [3H]DA Uptake Into 
Rat Striatal Synaptosomes and Synaptic Vesicles. 
To determine if modulation of DA uptake contributed to 
the increase in [3H]over?ow evoked by nicotine or lobeline, 
[3H]DA uptake into striatal synaptosomes and synaptic 
vesicles was determined (FIG. 5). Nicotine did not inhibit 
[3H]DA uptake into striatal synaptosomes over the concen 
tration range (0.001 nM—100 ,uM) examined. Before deter 
mining the effect of nicotine on synaptic vesicular [3H]DA 
uptake, the purity of the isolated synaptic vesicle preparation 
was determined by electron microscopy of representative 
vesicle preparations. Plain spheroid or ellipsoid synaptic 
vesicle pro?les of approximately 50 nm in diameter were the 
predominant membrane structures observed. Very few 
(2 1%) contaminating membrane fragments were present. 
The effect of nicotine on [3H]DA uptake into synaptic 
vesicles was analyZed by repeated-measures, one-way 
AN OVA which revealed a signi?cant nicotine concentration 
effect (F9>28=3.30, P<0.05). However, Dunnett’s post hoc 
analysis revealed that signi?cant inhibition of uptake only 
occurred at very high concentration (1 mM) of nicotine. 
Lobeline inhibited [3H]DA uptake into synaptopsomes in 
a concentration-dependent manner (FIG. 5). Repeated 
measures, one-way AN OVA revealed a signi?cant lobeline 
concentration effect (F9)38=154.0, P<0.0001). The lowest 
concentration of lobeline to produce a signi?cant inhibition 
in the synaptosomal preparation was 30 nM. The IC5O for 
lobeline to inhibit uptake into synaptosomes was 80:12 pM. 
Moreover, in contrast to nicotine, lobeline potently inhibited 
[3H]DA uptake into synaptic vesicles in a concentration 
dependent manner (F8)26=28.60, P<0.0001). The lowest con 
centration of lobeline to produce a signi?cant inhibition was 
0.3 pM, and complete inhibition was obtained at 10 nM. The 
IC50 value for lobeline to inhibit vesicular uptake was 
0.88:0.001 pM, which was 2-orders of magnitude lower 
than that for lobeline-induced inhibition of synaptosomal 
[3H]DA uptake. TetrabenaZine (0.001—100 pM), a high 
af?nity and speci?c inhibitor of the synaptic vesicular 
monoamine transporter (VMAT2), signi?cantly inhibited 
striatal vesicular [3H]DA uptake in a concentration 
dependent manner (F(9)28)=23.78, P<0.0001). The IC5O for 
tetrabenaZine was 77.7113 nM, and the lowest concentra 
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tion of tetrabenaZine which signi?cantly inhibited vesicular 
uptake was 0.07 nM. Complete inhibition was obtained at 1 
pM tetrabenaZine. Thus, lobeline was approximately one 
order of magnitude less potent than tetrabenaZine in inhib 
iting vesicular [3H]DA uptake. 
Effect of Lobeline on Endogenous DA and DOPAC Content 
in Rat Striatum. 
The marked increase in [3H]over?ow in response to 
superfusion with high concentrations of lobeline (FIGS. 2 
and 3) and the lobeline-induced inhibition of synaptosomal 
and vesicular [3H]DA uptake (FIG. 5) suggested that super 
fusion with lobeline may deplete striatal DA content. One 
way ANOVA revealed a signi?cant lobeline concentration 
effect on DA (F(6>41)=15.35, P<0.0001) and DOPAC (F(6) 
40)=6.90, P<0.0001) content in superfused striatal slices. 
Superfusion with low concentrations (0.1—10 nM) of 
lobeline did not alter DA or DOPAC content (data not 
shown); however, when slices were superfused with high 
lobeline concentrations (30—100 pM), lobeline signi?cantly 
depleted endogenous DA content and increased DOPAC 
content compared to a control (FIG. 6). 
To determine if lobeline-induced depletion of endogenous 
DA content occurred after in vivo administration of lobeline 
to rats, lobeline was administered (s.c.) acutely (0, 1, 3, 10, 
30 mg/kg), intermittently (0, 3, 10 mg/kg, once daily for 10 
days) or continuously (0, and 30 mg/kg, by osmotic 
minipump delivery for 21 days), and rat striata were 
obtained for the determination of endogenous DA and 
DOPAC content (See Table 4). Two-way AN OVA revealed 
that lobeline did not signi?cantly alter either striatal DA 
(F(4)58)=0.05, P>0.05) or DOPAC (F(4)58)=0.54, P>0.05) 
content. Therefore, lobeline administration in vivo did not 
deplete striatal DA content at any dose of lobeline or any 
treatment regimen examined. 
TABLE 4 
In vivo Administration of Lobeline Does Not Alter DA and DOPAC 
Content in Rat Striatum" 
Lobeline (mg/kg) 
0 1 3 10 30 
DA 739 z 64 756 z 111 761 z 103 841 z 76 665 z 126 
Acute 
Inter- 743 z 57 ND 778 z 27 800 z 41 ND 
mittent 
Chronic 840 z 72 ND ND ND 856 z 144 
DOPAC 
Acute 84 z 12 81 z 12 89 15 82 8 72 z 10 
Inter- 63 z 6 ND 57 _ 12 57 + 3 ND 
mittent 
Chronic 61 r 4 ND ND ND 62 r 10 
*Rat striata were obtained 1 hr after acute lobeline administration (0, 1—30 
mg/kg, s.c.); after intermittent lobeline administration (0,3 and 10 mg/kg, 
once daily injection for 10 days, s.c.); and after chronic lobeline delivery 
by osmotic minipump (0 and 30 mg/kg/day for 21 days, s.c.). Data are 
presented as mean : S.E. ng/mg protein. ND: not determined. n = 6-8 
rats/group. 
[3H]DTBZ Binding 
Equilibrium binding analysis was performed to determine 
the values of KD and Bmax for [3H]DTBZ binding to rat 
striatal vesicle membranes. Results revealed that the speci?c 
binding of [3H]DTBZ was saturable and represented 
60—80% of total binding of all [3H]DTBZ concentrations 
(0.5—10 nM) examined (FIG. 7). Speci?c [3H]DTBZ bind 
ing reached a plateau at a concentration of 3 nM. Nonspe 
ci?c binding increased linearly as a concentration of [3H] 
DTBZ increased. Scatchard analysis of the speci?c [3H] 
DTBZ binding revealed a KB of 1.67 nM and a Bmax of 8.68 











